The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28105277 |
33 |
Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors. |
Bristol-Myers Squibb |
27914800 |
11 |
Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. |
Universidade Federal Fluminense |
27994741 |
48 |
Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. |
Bristol-Myers Squibb R & D |
27612545 |
37 |
Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors. |
Bristol-Myers Squibb Research & Development |
27455395 |
66 |
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. |
Bristol-Myers Squibb R & D |
27015008 |
51 |
Atropisomer Control in Macrocyclic Factor VIIa Inhibitors. |
Bristol-Myers Squibb Research & Development |
26848109 |
8 |
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. |
Campus |
26704266 |
80 |
Novel phenylalanine derived diamides as Factor XIa inhibitors. |
Bristol-Myers Squibb |
26151189 |
56 |
Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors. |
TBA |
26005539 |
23 |
Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety. |
Bristol-Myers Squibb |
25728130 |
79 |
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. |
Bristol-Myers Squibb |
24224573 |
31 |
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors. |
Universidade De Lisboa |
23294255 |
114 |
Development of new cyclic plasmin inhibitors with excellent potency and selectivity. |
Philipps University Marburg |
22607152 |
7 |
Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. |
Universit£ |
22386244 |
4 |
Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening. |
Sanofi Pharmaceuticals |
10669559 |
180 |
Protease inhibitors: current status and future prospects. |
University of Queensland |
9301673 |
234 |
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. |
Klinikum Der Friedrich-Schiller-Universit£T Jena |
1527787 |
11 |
Synthesis and biological activity of ketomethylene pseudopeptide analogues as thrombin inhibitors. |
Thrombosis Research Institute |
10915051 |
43 |
The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position. |
Novartis Horsham Research Centre |
10091673 |
21 |
Synthesis of potent and selective inhibitors of human plasma kallikrein. |
The Procter & Gamble |
22047802 |
8 |
The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors. |
Universit£T Bielefeld |
| 78 |
Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitors |
TBA |
15801822 |
28 |
9-hydroxyazafluorenes and their use in thrombin inhibitors. |
Merck Research Laboratories |
15582418 |
103 |
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. |
Abbott Laboratories |
15149645 |
92 |
Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors. |
Abbott Laboratories |
15080981 |
72 |
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors. |
Millennium Pharmaceuticals |
15013006 |
69 |
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs. |
Millennium Pharmaceuticals |
14980671 |
78 |
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors. |
Millennium Pharmaceuticals |
14980670 |
107 |
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs. |
Millennium Pharmaceuticals |
12039584 |
59 |
Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors. |
Millennium Pharmaceuticals |
12039583 |
140 |
Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides. |
Millennium Pharmaceuticals |
32456431 |
24 |
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species. |
Bristol Myers Squibb |
30691925 |
34 |
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome. |
Glaxosmithkline R&D |
31521475 |
205 |
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors. |
Glaxosmithkline |
10425106 |
12 |
4-Heterocyclohexanone-based inhibitors of the serine protease plasmin. |
Brown University |
31005442 |
64 |
Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. |
Glaxosmithkline R&D |
9873535 |
13 |
Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics. |
Molecumetics |
26536069 |
89 |
Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor. |
Aarhus University |
7739010 |
118 |
Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. |
Thrombosis Research Institute |
7629790 |
32 |
New orally active serine protease inhibitors. |
Minase Research Institute |
2136920 |
39 |
New leupeptin analogues: synthesis and inhibition data. |
University of Arkansas |
29517911 |
87 |
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema. |
Bicycle Therapeutics |
29077405 |
63 |
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). |
Bristol-Myers Squibb |
28460818 |
29 |
Neutral macrocyclic factor VIIa inhibitors. |
Bristol-Myers Squibb Research and Development |
32321856 |
4 |
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. |
Shanghai Institute of Materia Medica |
20550146 |
32 |
Correlating solution binding and ESI-MS stabilities by incorporating solvation effects in a confined cucurbit[8]uril system. |
University of Cambridge |
11101352 |
88 |
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. |
Parke-Davis Pharmaceutical Research |
24058293 |
12 |
Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors. |
Durham University |
11784141 |
11 |
Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity. |
University of Queensland |